Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 3Mesothelioma, Malignant 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 1Non Hematologic Cancers 1Neoplasms, Mesothelial 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Lung Neoplasms 1Low Grade Serous Ovarian Cancer 1Carcinoma, Ovarian Epithelial 1Adenoma 1

Interventions

Paclitaxel 32Carboplatin 23liposomal doxorubicin 14pembrolizumab 12Topotecan 10Bevacizumab 10Gemcitabine 9mirvetuximab soravtansine 8olaparib 6Cisplatin 61-dodecylpyridoxal 6rucaparib 5Nivolumab 5Cyclophosphamide 5oregovomab 4farletuzumab 3catumaxomab 3Standard of Care 3Irinotecan 3Fulvestrant 3CCV-AV protocol 3talazoparib 2sacituzumab govitecan 2ribociclib 2phenoxodiol 2pegfilgrastim 2pazopanib 2palbociclib 2niraparib 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Ovarian Epithelial × defactinib × Clear all
NCT02943317 2019-04-30

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

Verastem, Inc.

Phase 1 Terminated
98 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡